| Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Co.'s primary areas of focus include viral diseases, inflammatory and fibrotic diseases and oncology. Co.'s products include: Biktarvy for the treatment of HIV-1 infection in certain patients; Vosevi®, a single tablet regimen of sofosbuvir, velpatasvir and voxilaprevir for the re-treatment of chronic hepatitis C virus infection in adults; Vemlidy® for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease; and Yescarta (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. We show 46 historical shares outstanding datapoints in our GILD shares outstanding history coverage, used to compute GILD market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing GILD market cap history over the course of time is important for investors
interested in comparing GILD's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of GILD versus a peer is one thing; comparing
GILD market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like GILD can fluctuate over the course of history.
With this page we aim to empower investors researching GILD by allowing them to research the GILD market cap history.